Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

47
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
47
Drug Therapy01:28

Drug Therapy

346
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
346
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

334
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
334
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

49
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
49
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

242
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
242
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

66
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
66

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Sub-Saharan Africa's Hypertension Care Crisis Through a Data-Driven Approach.

Journal of the American College of Cardiology·2025
Same author

Adapting Cardiovascular Disease Data to Inform Policy Goals: Global to Local.

Journal of the American College of Cardiology·2025
Same author

WHF Roadmap on Single Pill Combination Therapies.

Global heart·2025
Same author

Evaluating Blood Pressure Response Patterns to Exercise Stress Testing.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Low-Dose Combinations With 3 or 4 Blood Pressure-Lowering Medications for the Treatment of Hypertension.

JACC. Advances·2025
Same author

Consumer perceptions and preferences of pharmacist-led professional services and attributes in Australia: a qualitative focus group study.

BMJ open·2025
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 6, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.7K

Putting polypills into practice: challenges and lessons learned.

Ruth Webster1, Jose M Castellano2, Oyere K Onuma3

  • 1George Institute for Global Health, University of Sydney, Sydney, Australia.

Lancet (London, England)
|March 15, 2017
PubMed
Summary
This summary is machine-generated.

Cardiovascular polypills improve patient adherence and risk factors for heart disease. Widespread implementation faces challenges like lack of reimbursement and physician buy-in, hindering public health benefits.

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.5K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

Related Experiment Videos

Last Updated: Mar 6, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.7K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.5K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

Area of Science:

  • Cardiovascular Medicine
  • Public Health Policy
  • Pharmacology

Background:

  • Regulatory approvals for cardiovascular polypills are expanding globally.
  • Polypills demonstrate improved adherence and risk factor control in patients with cardiovascular disease or high risk.
  • Existing clinical trial data support polypill efficacy and safety.

Purpose of the Study:

  • To review the clinical impact and implementation challenges of cardiovascular polypills.
  • To identify barriers to widespread clinical adoption and public health benefit realization.

Main Methods:

  • Analysis of clinical trial literature on polypill strategies.
  • Review of real-world implementation experiences following commercial rollout.
  • Assessment of factors influencing physician uptake and government reimbursement.

Main Results:

  • Polypills significantly improve adherence and cardiovascular risk factor control compared to usual care.
  • Cost-effectiveness and safety of polypill use are supported by clinical evidence.
  • Key implementation barriers include lack of government reimbursement and low physician adoption.

Conclusions:

  • Cardiovascular polypills offer substantial clinical benefits but face significant real-world implementation hurdles.
  • Overcoming barriers requires coordinated efforts in education, advocacy, and policy changes.
  • Global agencies, national bodies, and governments must endorse and support polypill integration for maximum public health impact.